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Abstract
Background: Elevated SNCA gene expression and intracellular accumulation of the encoded α-synuclein (aSyn)
protein are associated with the development of Parkinson disease (PD). To date, few enzymes have been
examined for their ability to degrade aSyn. Here, we explore the effects of CTSD gene expression, which encodes
the lysosomal protease cathepsin D (CathD), on aSyn processing.
Results: Over-expression of human CTSD cDNA in dopaminergic MES23.5 cell cultures induced the marked
proteolysis of exogenously expressed aSyn proteins in a dose-dependent manner. Unexpectedly, brain
extractions, Western blotting and ELISA quantification revealed evidence for reduced levels of soluble
endogenous aSyn in ctsd knock-out mice. However, these CathD-deficient mice also contained elevated levels of
insoluble, oligomeric aSyn species, as detected by formic acid extraction. In accordance, immunohistochemical
studies of ctsd-mutant brain from mice, sheep and humans revealed selective synucleinopathy-like changes that
varied slightly among the three species. These changes included intracellular aSyn accumulation and formation of
ubiquitin-positive inclusions. Furthermore, using an established Drosophila model of human synucleinopathy, we
observed markedly enhanced retinal toxicity in ctsd-null flies.
Conclusion: We conclude from these complementary investigations that: one, CathD can effectively degrade
excess aSyn in dopaminergic cells; two, ctsd gene mutations result in a lysosomal storage disorder that includes
microscopic and biochemical evidence of aSyn misprocessing; and three, CathD deficiency facilitates aSyn toxicity.
We therefore postulate that CathD promotes 'synucleinase' activity, and that enhancing its function may lower
aSyn concentrations in vivo.
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Background
α-Synuclein (aSyn) is a cytosolic and presynaptic protein
strongly implicated in the pathogenesis of neurodegener-
ative disorders. Point mutations in the corresponding
gene, SNCA, as well as over-expression of the wild-type
variant due to locus multiplication, cause autosomal-
dominant forms of Parkinson disease (PD) [1-3]. Further-
more, accumulation of aggregated, insoluble aSyn is a
hallmark of many other neurodegenerative diseases,
including sporadic PD, dementia with Lewy bodies
(DLB), multiple system atrophy (MSA), the Lewy body
variant of Alzheimer's disease, and PANK2-linked neuro-
degeneration. Collectively, these disorders are referred to
as synucleinopathies [4-7]. These observations from
human studies and related insights from multiple verte-
brate and invertebrate animal models of SNCA over-
expression (reviewed in: [8]) demonstrate that both wild-
type and mutant forms of aSyn can induce neurodegener-
ation [9-13].
Given that aSyn inclusions are a pre-requisite feature of
synucleinopathies, the processing of aSyn has been exam-
ined extensively in both ex vivo and in vivo models. These
investigations have focused either on post-translational
modifications of aSyn [14] or on mechanisms of degrada-
tion. Initially, a key role had been postulated for the ubiq-
uitin proteasome pathway (UPP) in the degradation of
aSyn, because mutations in two UPP-related genes, Parkin
and UchL-1 have been shown to influence PD risk [15-18]
and because molecular, cellular and animal studies linked
these genes to UPP-dependent processing of aSyn [19-21].
However, growing evidence has indicated that the lyso-
some, as well as the proteasome, can mediate degradation
of aSyn [22,23]. In general, proteins are sequestered
within lysosomes by one of three known methods, i.e.,
macroautophagy, microautophagy, and chaperone-medi-
ated autophagy (CMA) (reviewed in [24]). Of these, it
appears that aSyn can be a substrate for both macroau-
tophagy and CMA [25-28].
Regardless of the exact autophagic pathway by which aSyn
enters the lysosome, it is assumed that it undergoes rapid
degradation by a proteolytic enzyme (or enzyme complex,
referred to as 'synucleinase/s'). Cathepsins are lysosomal
proteases whose enzymatic activity is conferred by critical
residues, e.g., serine, cysteine or aspartic acid. Cathepsin D
(CathD) is a major lysosomal aspartyl protease composed
of two disulfide-linked polypeptide chains, both pro-
duced from a single protein precursor [29]. Interestingly,
CathD deficiency and its enzymatic inactivation in either
humans, sheep, dogs or mice results in an early-onset,
progressive and ultimately fatal neurodegeneration,
which has been classified as one of several 'neuronal
ceroid lipofuscinoses' (NCL) [30-34]. In vitro experiments
indicated that the treatment of recombinant aSyn with
CathD resulted in partial aSyn proteolysis [35]. Recently,
Sevlever et al. confirmed a proteolytic effect of CathD in in
vitro digestion studies and extended their work to lyso-
somal fractions using human neuroblastoma cells over-
expressing SNCA cDNA [36].
Here, we first examined the ability of CathD to regulate
both wild-type and mutant aSyn in a dopaminergic cell
culture system, and then examined the brains of several
CathD-deficient mammals with NCL for evidence of mis-
processing of endogenous aSyn. Finally, we tested the
effects of ctsd expression on neuronal aSyn toxicity in a
well-described Drosophila model of synucleinopathy. Our
data indicate that ectopically expressed CathD enhances
degradation of wild-type and mutant aSyn proteins, and
that absence or deficiency of CathD promotes aSyn aggre-
gation and toxicity in vivo.
Methods
Plasmid constructs and establishment of MES-hSNCA cell 
model
The human SNCA gene contained in the pcDNA3.1 vector
was a kind gift of Prof. P.T. Lansbury. The rat SNCA gene
was cloned out of a rat brain cDNA library using the prim-
ers GATATCGCCACCATGGATGTGTTCATGAAAGGACTT
(forward) and CAAGACTATGAGCCTGAAGCCTCT-
TCTAGA (reverse), and inserted into the pcDNA3.1 vector
(Invitrogen) using the EcoRV and Xba1 restriction sites.
pCMV-XL5 vector with and without the human CTSD
gene was purchased from Origene's TrueClone collection.
All constructs were isolated from DH5alpha E. coli using
Qiagen's Maxiprep kit. To create the Ala30Pro, Glu46Lys,
Ala53Thr, Ser129Ala, Ser129Asp, and Asp98Ala/
Gln99Ala mutants of human SNCA, site directed muta-
genesis was performed using Stratagene's QuikChange kit.
All constructs were sequence verified prior to use.
The dopaminergic rodent mesencephalic cell culture sys-
tem (MES 23.5 cells) was a gift of S Appel, Baylor College
of Medicine. Cells seeded at a density of 6 million per 10
cm dish onto poly-D-Lysine coated plates (BD Falcon),
were transiently transfected using Lipofectamine 2000
(Invitrogen Corp). Cells were routinely transfected with
0.5 μg (per 10 cm dish) of SNCA plasmid (either human
wt, rat wt, or human mutant) and with 0–5 μg (per 10 cm
dish) of wt CTSD plasmid. The total amount of DNA was
normalized to 5.5 μg (per 10 cm dish) using empty
pCMV-XL5 vector. 24 hours later, cells were washed with
Tris-buffered saline and lysed in 140 mM NaCl, 50 mM
Tris-HCl, pH 8.0, 1 mM EDTA, 0.5% Triton-X100, and 1×
protease inhibitors, as described [37]. Lysates were centri-
fuged at 100,000 g for 30 min at 4°C; the top 2/3 of super-
natants were removed and frozen in siliconized tubes at -
80°C. The activity of LDH (lactate dehydrogenase) in the
conditioned medium of transfected MES23.5 cells wasMolecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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routinely assayed; cellular metabolism was measured by
the conversion of MTT [(3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) to formazan, as
described [38]. For these standard toxicity assays, a posi-
tive control leading to 100% cell lysis (0.1% Triton-X 100
treatment) was run in parallel.
Antibodies, Western blotting and ELISA
The rabbit polyclonal 7071AP, hSA-2 and mSA-1 antibod-
ies (Abs) were raised and affinity-purified at Open Biosys-
tems, Inc. (http://www.openbiosystems.com) against
recombinant, full-length aSyn, which had been HPLC-
and mass spectrometry-characterized and subjected to
amino acid composition and protein concentration anal-
yses [39]. Cell lysates were analysed by SDS-PAGE as
described [40]. The monoclonal aSyn antibody, Syn-1,
was purchased from BD Clontech, the monoclonal anti-
Ser129Phos antibody was from Dako, and the goat poly-
clonal anti-CathD antibody was from Santa Cruz.
Lysates were analysed for aSyn content by a 384-well
quantitative sandwich ELISA (enzyme-linked immune-
adsorbant assay), as described in detail elsewhere [39,40],
using hSA-2 Ab for coating and biotinylated Syn-1 Ab as
the readout Ab. Color development was carried out by
using Fast-p-Nitrophenyl Phosphate (Sigma) and moni-
tored kinetically at OD 405 nm every 5 min for up to 60
min. For serial dilutions of cell lysates on the ELISA plate,
blocking buffer containing 0.5% lysate from vector-trans-
fected cells was used as diluent; the same was used to cre-
ate the corresponding standard curve of recombinant
human aSyn (Additional file 1, Fig. S1A). Saturation
kinetics were examined for identification of time point(s)
where standards and sample dilutions were in the log
phase. When analyzing cell lysates by ELISA [hSA2/Syn1-
B], we recorded concentrations in MES-hSNCA cells that
showed the expected parallelism after serial dilution (e.g.,
the 1:2000 dilution gave a value approximately twice that
of the 1:4000 dilution; Additional file 1, Fig. S1B), that
were SNCA cDNA dose-dependent (Additional file 1, Fig.
S1C), and that permitted the precise calculation of the
total aSyn protein concentration (pg per total protein in
μg) expressed in living cells.
Immunohistochemistry and histochemistry
Ctsd -/- mice produced by Saftig and colleagues [41] were
maintained on a mixed C57BL6J strain background in the
animal facility of the Helsinki University, Biomedicum,
where food and water were available ad libitum and the
light/dark cycle was 12/12 hours. The study protocol was
approved by the Ethical Committee of Helsinki Univer-
sity. Mice were decapitated at the age of 24 days and
brains were collected. For immunohistochemistry, one
hemisphere was immersion fixed in 4 per cent neutral
buffered paraformaldehyde, dehydrated and embedded
in paraffin, while the other hemisphere was frozen for
biochemistry.
Archival paraffin-embedded brain specimens of sheep
with congenital ovine NCL (due to a homozygous mis-
sense mutation in the CTSD gene) and of three infants
with congenital NCL (due to a homozygous duplication
event in CTSD and an unknown gene defect leading to
absence of CathD in tissue) were analysed by immunohis-
tochemistry, as described [30,31]. Four μm-thin paraffin
sections were dewaxed in xylene and descending alcohol
series. Endogenous peroxidase activity was blocked by
incubation in methanol containing 1.6% hydrogen perox-
ide, 30 min at RT. Sections were then rinsed 3 × with PBS
and blocked with 15% normal serum, 30 min at RT,
before O/N incubation at 4°C with primary antibody.
Sections were washed 3 × 5 min with PBS and incubated
with biotinylated secondary antibody and avidin coupled
peroxidase for 30 min RT (mouse Vectastain Elite ABC kit,
Vector laboratories, Peterborough, UK), and stained with
aminoethyl carbazole as substrate. Sections were counter-
stained with hematoxylin. Immunohistochemistry of
ovine brain sections was carried out as described in detail
elsewhere [37,42].
The SNCA-expressing and the CathD-deficient Drosophila
lines have been described previously [9,43]. These lines
were crossed with each other to obtain flies expressing
human aSyn wild-type (WT) in the absence of CathD. Ctsd
genotypes were verified using a PCR-amplification of the
fly ctsd locus on chromosome 2. Flies expressing either
human aSyn WT in wt background and ctsd-null flies not
expressing aSyn were used as controls. Flies were fixed in
4 per cent buffered paraformaldehyde, dehydrated and
embedded in paraffin. Four mm-thin sections were
stained with haematoxylin-eosin.
Mouse brain homogenization and fractionation
For initial examination of the central nervous system, fro-
zen brains (without cerebellum and brain stem) from 24-
day old wt and ctsd-/- mice were homogenized in 40 mM
Tris-Cl, pH 7.4 containing protease inhibitor cocktail
(Complete, Amersham) and centrifuged at 1,500 g for 10
min at 4°C. These supernatants were used for Western
analyses and called Tris-extracts. For serial extraction
experiments, frozen brains (including the brain stem and
cerebellum) from 24-day old wt and ctsd-/- mice were
homogenized in lysis buffer (STEN LB, 50 mM Tris-HCl,
pH 7.5, 140 mM NaCl, 2 mM EDTA, protease inhibitor
cocktail, and 0.4 per cent NP-40), as described [37].
Homogenates were centrifuged at 100,000 g for 45 min at
4°C to collect the NP-40 supernatant. The pellet was sus-
pended in STEN LB containing 1% SDS, followed by cen-
trifugation at 100,000 g for 45 min at 12°C to collect the
SDS supernatant; the remaining SDS pellet was suspendedMolecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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in 600 μl of STEN LB containing 1% formic acid (FA) and
left overnight on a shaker at 4°C.
Results
Ectopic Cathepsin D effectively degrades wild-type and 
mutant α-synuclein in dopaminergic cells
To investigate whether CathD has any effect on aSyn turn-
over, we utilized a rodent cell line of mesencephalic ori-
gin, MES23.5, which constitutively synthesizes dopamine
[38,44,45]. At baseline, MES23.5 cells show very low lev-
els of endogenous ctsd and snca gene expression (Fig. 1A).
Therefore, we co-expressed untagged wild-type (wt)
human  SNCA  cDNA with increasing amounts of
untagged, wt human CTSD in these cells. After 24 hours of
co-expression, we observed by Western blotting that as the
levels of the mature, 32 kDa CathD protein increased, the
signal intensity of the 16 kDa, full-length (FL) aSyn mon-
omer decreased (Fig. 1A). Of note, this decrease in aSyn
Over-expression of Cathepsin D lowers α-synuclein in dopaminergic cells Figure 1
Over-expression of Cathepsin D lowers α-synuclein in dopaminergic cells. (A) Western blot analyses under reduc-
ing conditions of MES23.5 cells [38] expressing untagged, wild-type human SNCA (hSNCA WT) or vector (vec) plasmid DNA 
following transfection with increasing amounts of CTSD cDNA. Lysates collected 24 hours after transfection show an inverse 
decrease in the level of full-length (FL) α-synuclein (aSyn), as shown with polyclonal antibodies (Ab), 7071AP [46], hSA-2 
[39,40], and monoclonal Ab Syn-1 (not shown); anti-β-actin was used as loading control. Note, no low molecular fragments of 
aSyn are detected under these conditions. (B) ELISA [hSA2/Syn1-B] and statistical analyses of MES-aSyn cells transfected with 
increasing amounts of CTSD cDNA, demonstrating the quantitation of the aSyn-lowering effect by ectopic Cathepsin D (**, P < 
0.01; ***, P < 0.001). Note, the addition of Pepstatin A to the cell lysis buffer did not change the observed reduction of the 
intracellular aSyn concentration (up to < 80 per cent). (C) ELISA [hSA2/Syn1-B] and statistical analyses of MES23.5 cells dem-
onstrating the quantitation of ectopic Cathepsin D expression (5 μg per dish) on mutant aSyn proteins and wild-type rat aSyn 
(see text for details). Data in (B) and (C) are expressed as mean [± standard deviation] of the intracellular concentration of 
aSyn (in pg/per μg total protein) in MES23.5 cell lysates from each dish and graphically displayed in per cent numbers of vector 
control without ectopic CTSD expression. Graphs reflect six independent experiments.
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monomer was not accompanied by an increase in lower
molecular weight fragments of aSyn, as examined by
longer exposure of Western blots with four different anti-
bodies that had previously shown reactivity with both FL
aSyn and C-terminally truncated aSyn species in vivo (Syn-
1, 7071AP; hSA-2; mSA-1; Additional file 2, Fig. S2)
[39,46]. Similarly, none of these four antibodies detected
any CathD-induced cellular accumulation of insoluble or
higher molecular weight aSyn species. Furthermore, we
confirmed by LDH and MTT assays that the observed
effect of CathD on lowering of aSyn was not caused by a
decrease in cellular integrity or metabolic activity. Impor-
tantly, co-expression of aSyn with plasmids encoding
three other untagged, wild-type, human lysosomal
enzymes (i.e., cathepsin E, cathepsin L and sulphotrans-
ferase), which were expressed under the same promoter as
CTSD and analyzed as above, did not lower the intracellu-
lar aSyn concentration (data not shown).
To quantify precisely the efficiency of CathD-induced
reduction of aSyn in our cell culture model, we employed
a sandwich-type enzyme-linked immunoabsorbent assay
(ELISA [hSA2/Syn1-B pair]), that is both specific and sen-
sitive for the quantification of cellular aSyn concentra-
tions (Additional file 1, Fig. S1; [39,40]). As shown in Fig.
1B, we consistently recorded a significant, dose-depend-
ent decrease in soluble aSyn with ectopic CathD expres-
sion, which peaked at 5 μg CTSD cDNA per 10 cm dish.
Importantly, the effect of CathD on aSyn occurred in liv-
ing cells, because the addition of the specific CathD inhib-
itor, pepstatin A, to our lysis buffer did not alter the
outcome (Fig. 1B).
Heritable PD has been linked to distinct point mutations
within the SNCA gene; furthermore, sustained phosphor-
ylation of aSyn at residue Ser129 has been found in brain
specimens of virtually all human synucleinopathies
[14,47]. Therefore, we next examined the effect of human
CathD on these aSyn variants by expressing degradation
efficiency as a percentage of the signal obtained from each
relevant mutant in the absence of CathD. As shown in Fig.
1C, CathD over-expression efficiently promoted the deg-
radation of the three known PD-linked aSyn mutants, i.e.,
Ala30Pro, Glu46Lys and Ala53Thr. Furthermore, CathD
over-expression also efficiently degraded two other aSyn
variants, which we engineered to abrogate and mimic
phosphorylation at Ser129, i.e., Ser129Ala and
Ser129Asp, respectively. Similarly, exogenous CathD was
able to lower the levels of full-length rat aSyn, using the
same paradigm (Fig. 1C).
According to Cuervo and colleagues, residues Asp98 and
Gln99 represent a putative motif by which aSyn is recog-
nized by the hsc70 chaperone complex preceding chaper-
one-mediated autophagy and degradation [28]. To
investigate the importance of this motif for CathD in low-
ering aSyn ex vivo, MES23.5 cells were transfected with an
aSyn variant where these two critical residues were
changed to Alanine (DQ/AA-aSyn); CathD expression
reduced DQ/AA aSyn as efficiently as wt aSyn in these
MES23.5 cells when analyzed 24 hours after transfection
(Fig. 1C).
Soluble α-synuclein levels are reduced in Cathepsin D-
deficient mouse brain
To determine the role of CathD on endogenous aSyn
metabolism in vivo, we utilized a well characterized ctsd
knock-out (ctsd-/-) mouse model. These mice carry two
null alleles of murine ctsd and develop a fatal NCL leading
to premature death at day 26 ± 1 [33,41]. We first exam-
ined aSyn levels in the brain of ctsd-/- mice and their wild-
type (wt) littermates by SDS/PAGE and Western blotting
under both non-reducing (Fig. 2A) and reducing condi-
tions (Fig. 2B). We found that the 16 kDa aSyn monomer
was slightly but consistently less abundant in Tris-extracts
of ctsd-/- brain (without cerebellum and brain stem) when
compared with littermate controls (n = 4 per group for
non-reducing conditions; n = 16 per group for reducing
conditions). In these extracts, we found no evidence of
truncated aSyn species by Western blotting (Fig. 2A, B;
and data not shown). In parallel, the amount of mono-
meric, full-length β-synuclein protein (17 kDa) appeared
unchanged in ctsd-/- versus wt control mouse brains (Fig.
2C), although higher molecular weight species (and pos-
sibly truncated variants) appeared increased (Fig. 2C;
note, the latter findings could not be corroborated with
another Ab due to lack of availability). In addition to the
somewhat unexpected reduction of the 16 kDa aSyn pro-
tein in ctsd-null brains, we observed that the mouse mon-
oclonal aSyn Ab, Syn-1, also visualized bands that
migrated at molecular weights of 25 kDa, 50 kDa (reduc-
ing conditions; Fig. 2B) and > 150 kDa positions (non-
reducing, Fig. 2A). These bands were interpreted as endog-
enous immunoglobulin chains, as they were also detected
by anti-mouse secondary Ab alone (not shown).
In order to further substantiate and expand these observa-
tions, we carried out a serial fractionation protocol of
whole mouse brain (including cerebellum and brain
stem) using an initial NP-40 detergent extraction step fol-
lowed by a SDS extraction step of the remaining NP-40
pellets. There, we blinded the operator regarding the gen-
otype, analyzed fractions by both immunoblotting with
multiple Abs (Fig. 3A, 3B) and by sandwich ELISA (Fig.
3C), and then confirmed the genotype by probing for the
presence (or absence) of CathD in all specimens (Fig. 3A).
In agreement with the results obtained in Tris extracts, our
serial fractionation and ELISA quantification demon-
strated a reduction – rather than an increase – in the levels
of soluble aSyn in ctsd-/- mouse brains (n = 8) when com-Molecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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pared with their WT (n = 4) littermates; the reduction
measured 18.6 and 20.0 per cent in NP-40 and SDS frac-
tions, respectively (Fig. 3C). In addition, using densitom-
etry we quantified the low molecular weight species of
aSyn (migrating at 12.5 and 10 kDa positions) that were
detected in NP-40 extracts by mSA-1 (Fig. 3A; Additional
file 2, Fig. S2), but we found no apparent difference
between the two genotypes (not shown).
Insoluble α-synuclein oligomers are elevated in Cathepsin 
D-deficient mouse brain
To complete the serial extraction protocol, we next
searched for the presence of insoluble aSyn species in the
formic acid extracts of SDS pellets from the ctsd-/- mouse
brains shown in Fig. 3. There, we specifically searched for
HMW aggregates of aSyn (referred to as oligomers)
employing our most sensitive Abs (Fig. 4A). Independent
Western blotting with hSA-2 and mSA-1 (Fig. 4A) and
subsequent densitometry of the ratio, aSyn to actin,
revealed more insoluble, HMW oligomers in ctsd-/- than
in WT mouse brain (Fig. 4B). Of note, these oligomers
Mice lacking ctsd gene expression show reduced levels of endogenous α-synuclein in Tris-soluble brain extracts Figure 2
Mice lacking ctsd gene expression show reduced levels of endogenous α-synuclein in Tris-soluble brain extracts. 
Western blot analyses of Tris brain extracts from 24-day old, wild-type (+) and ctsd-null mice (-) carried out under non-reduc-
ing (A) and reducing (B) conditions. Probing with monoclonal aSyn Ab, Syn-1 (and rabbit anti-mouse IgG secondary Ab) dem-
onstrates a subtle reduction in the full-length, monomeric aSyn protein (aSyn, FL) at the 16 kDa position in ctsd-null mice. 
Representative examples of 24 mouse brains are shown (n = 4 per genetic group under non-reducing conditions; n = 16 per 
genotype under reducing conditions). The same blots reveal a broad, high molecular weight (HMW) band above 150 kDa (tri-
ple asterisks), and reactive bands at 50 kDa (double asterisks) and 25 (asterisk) kDa positions under non-reducing (A) and 
reducing (B) conditions, respectively. (C) Immunoblotting with anti-β-synuclein Ab under reducing conditions reveals no differ-
ence at the 17 kDa monomeric (β-Syn, FL) protein position, but indicates elevation of lower molecular weight fragment(s) at 
~13 kDa (β-Syn, ΔC) and a HMW-immunoreactive smear in cathD-deficient mice. (Note, no additional anti-β-synuclein Ab is 
available for corroboration).
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migrated predominantly at the interface of the stacking
gel and running gel; their difference between the two gen-
otypes was estimated to be ~15 per cent, as detected by
both Abs (Fig. 4A and 4B; and data not shown). Intrigu-
ingly, these formic acid extracted aSyn oligomers evi-
dently did not co-localize with the HMW ubiquitin
positive smears, as the latter were predominantly found in
SDS extracts (Fig 4C).
Cathepsin D deficiency promotes intracellular α-synuclein 
accumulation in mouse brain
Our biochemical data showed a reduction of detergent
soluble aSyn and an increase of formic-acid soluble aSyn
species in ctsd-/- mouse brains. In human PD, DLB and
MSA brain, the formic acid-soluble or urea-soluble frac-
tions contain HMW aSyn aggregates. Therefore, we next
explored whether any aSyn aggregates were also detecta-
ble in brains of 24-day old ctsd-/- mice by immunohisto-
CathD-deficient mice show reduced α-synuclein levels in detergent soluble brain extracts Figure 3
CathD-deficient mice show reduced α-synuclein levels in detergent soluble brain extracts. Western blot analyses 
of fractionated whole brain homogenates from 24-day old, wild-type (+) and ctsd-/- mice (-) carried out under reducing condi-
tions showing NP-40 (A) and SDS extracts (B). Immunoblots were probed with anti-aSyn Abs (Syn-1; mSA-1), anti-β-actin and 
anti-CathD Abs. Primary Ab detection was carried out with sheep anti-mouse and donkey anti-rabbit Ab, respectively. Under 
these immunoblotting conditions, variable amounts of the 16 kDa aSyn monomer (aSyn, FL) and traces of 12.5 kDa and 10 kDa 
(aSyn, ΔC) aSyn-reactive proteins are detectable; no reproducible > 150, 50 and 25 kDa aSyn-positive bands are seen.(C) 
ELISA [hSA2/Syn1-B] quantification of NP-40 and SDS extracts from ctsd wild-type (WT) and mutant ctsd-/- (KO) mouse brains 
and of snca WT and snca-/- (KO) lysates serving as positive and negative controls. Ctsd-genotyped brain extracts were loaded 
in triplicates at three different dilutions each (1:500 to 1:2,000) onto a 384-well plate and read at 405 nm, as described [39,40]. 
Note, the absence of OD405 nm signals in snca KO mouse tissue. Bar graphs represent the mean group values (± SD) of mice 
that were individually analyzed (numbers as in A-C). The concentrations of total aSyn (in ng/μl) present in NP-40 extracts 
measured: ctsd WT, 1.34 ± 0.25; ctsd KO, 1.09 ± 0.26; and in the SDS fractions: ctsd WT, 0.60 ± 0.25; and ctsd KO, 0.48 ± 0.28.
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chemistry (Fig. 5). To avoid any cross-reactivity of the
secondary anti-mouse Ab with endogenous immunoglob-
ulins, we employed our rabbit polyclonal, affinity-puri-
fied anti-aSyn Abs (mSA-1 and hSA-2), whose binding
specificity for mammalian aSyn was confirmed using snca-
null tissue (Additional file 2, Fig. S2) [39,40,48,49]. As
shown in Fig. 5, we recorded prominent aSyn staining in
the neuropil of the cerebral cortex, thalamus and cerebel-
lum of control mice, as expected from its known presyn-
aptic localization (Fig. 5D to 5F). In contrast, brain
sections of ctsd-/- mice, processed in parallel, showed a
less prominently stained neuropil, particularly in the tha-
lamus (Fig. 5A, B). Intriguingly, in these CathD-deficient
mice, we also detected aSyn-positive aggregates within
select neurons of the deep cortical laminae, superior col-
liculi, the subiculum, as well as in the thalamus, deep cer-
ebellar nuclei, and even within white matter tracts (Fig.
5A–C). Intra-neuronal cytoplasmic accumulations
appeared large, while those within the thalamus were rel-
atively small, thereby suggesting their localization within
neurites. We concluded from these collective mouse data
that: one, the distribution and processing of endogenous
aSyn is altered in ctsd-/- mice; and two, murine CathD
deficiency promotes an early-onset NCL phenotype that
features the accumulation of a small pool of aSyn within
an insoluble brain compartment.
CathD-deficient brains show increased HMW α-synuclein-positive oligomers in formic acid extracts Figure 4
CathD-deficient brains show increased HMW α-synuclein-positive oligomers in formic acid extracts. (A) West-
ern blot analyses carried out under reducing conditions of formic acid extracts obtained from previously generated SDS pellets 
of wild-type (+) and ctsd-/- (-) mouse brains (see Fig. 3 above). Immunoblots were probed with high sensitivity, polyclonal aSyn 
Abs, hSA-2 and mSA-1, and anti-β-actin Ab, as indicated. Under these conditions, HMW aSyn-positive smears and trace 
amounts of monomeric, 16 kDa aSyn (aSyn, FL) are detectable in these formic acid extracts.(B) Quantification of aSyn-reactive 
species by densitometry examining the ratio of HMW smears (blue bars) and 16 kDa monomer (empty bars) versus the signal 
of β-actin-positive bands. Note, an ~15 per cent increase in HMW oligomers of aSyn is detected in formic acid extracts of ctsd-
/- brain by independent analysis of both mSA-1 (B) and hSA-2 immunoblots. (C) NP-40 and SDS extracts probed with anti-
ubiquitin consistently reveal HMW immunoreactive smears in SDS brain extracts of ctsd-/- mice. Representative examples of 
twelve mouse brains are shown (n = 4, ctsd+/+; n = 8, ctsd-/-).
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Mutant Cathepsin D expression alters α-synuclein 
immunohistochemistry in sheep brain
To validate these results in a second mammal, we carried
out immunohistochemical studies in a sheep colony
affected by congenital NCL (Fig. 6) [31]. This phenotype
is caused by a homozygous missense mutation in the
ovine CTSD gene (Gln934Ala), which renders the enzyme
proteolytically inactive despite a 5- to 10-fold over-abun-
dance of the mutant protein in the forebrain [50]. In sur-
veys of sagittal hemibrain sections with our panel of
mono- and polyclonal Abs to mammalian aSyn, overall
staining of the neuropil appeared relatively normal in
affected sheep (Fig. 6A; n = 3 for NCL sheep; n = 1 for het-
erozygous sheep; n = 2 for wt control sheep). However,
staining with our polyclonal Abs for ovine aSyn demon-
strated widespread areas of elongated axonal swelling in
deep white matter tracts in affected sheep (Fig. 6D) and
revealed isolated aSyn aggregates in the thalamus, similar
to the mice (not shown). As expected, no axonal abnor-
malities or aggregates were seen in heterozygous (Fig. 6B)
and wt animals (not shown). Intriguingly, when we
probed the sections with a well characterized monoclonal
Ab to phosphoSer129-aSyn, we observed a small number
of neurons in the cingulate cortex that showed intense
intracellular labeling in homozygous CTSD mutant sheep
(Fig. 6A), but not in heterozygous (Fig. 6B) and wt sheep.
Of note, the axonopathy detected by the polyclonal Abs to
aSyn was not matched by anti-phosphoSer129-aSyn reac-
tivity. The changes in aSyn reactivity described above
appeared specific, as staining of CathD-deficient sheep
brain sections with Abs to Alzheimer's-linked phosphor-
ylated tau, and TDP-43 did not reveal any obvious abnor-
malities (not shown). In contrast, development of
sections with a monoclonal anti-ubiquitin Ab revealed
extensive inclusion formation that was present in NCL
sheep brain throughout the cortex (Fig. 6C), including the
Mice lacking ctsd gene expression exhibit intracellular α-synuclein accumulation in several regions of the brain Figure 5
Mice lacking ctsd gene expression exhibit intracellular α-synuclein accumulation in several regions of the brain. 
Serial, paraffin-embedded sections from 24-day old cathepsin D knock-out mice (CathD) (A-C) and age-matched, wild-type 
control (D-F) mice (n = 5) were probed by immunohistochemistry with affinity-purified, polyclonal aSyn Ab, hSA-2. (A) In the 
frontal cortex of cathepsin D knock-out mice, scattered neurons with prominent intracellular aSyn-reactivity are detectable 
(arrows). (B) In the thalamus of CathD-deficient mice, the neuropil staining is reduced when compared with control animals, 
and small grain-like aggregates of aSyn are visible. (C) In the cerebellum of CathD deficient mice, abnormal aSyn-positive accu-
mulations of varying size can be observed in the granular cell layer and deep nuclei; those that appear cytoplasmic are identified 
by arrows. (D-F) As expected, aSyn-positive aggregates are not found in age-matched, wild-type mice processed in parallel. 
CC denotes corpus callosum. Scale bar, 25 μm.Molecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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cingulate cortex, but was absent in heterozygote and wt
animals.
Cathepsin D deficiency promotes α-synuclein 
accumulation in human newborns
Next, we analyzed serial sections of paraffin-embedded,
post mortem human brains from three infants diagnosed
with congenital NCL (Fig. 7). One of the three patients
carried a homozygous duplication (c.764 dupA) in exon 6
of the CTSD  gene, thereby creating a premature stop
codon and loss of CathD expression; another patient was
his older sibling, who died of the same disease phenotype
and thus, most probably, carried the same mutation,
while the third, unrelated patient with congenital NCL
had no detectable CathD protein present in her tissues
although she remains genetically unidentified [30]. The
brains of these three children revealed extreme atrophy
with massive neuronal loss throughout the cortex, accom-
panied by generalized glial activation [30,51]. Using the
same Ab panel employed above, we observed markedly
reduced aSyn staining in the cortical neuropil of affected
infants (Fig. 7B) compared to control brain (Fig. 7A), sim-
ilar to the changes seen in ctsd-/- mutant mouse brain
above. In addition, we identified strongly aSyn-reactive
neurons scattered throughout the neocortex (Fig. 7B).
These neurons carried cytoplasmic aSyn accumulations
that appeared granular and were visible throughout the
soma (Fig. 7B). Prominent 'synucleinopathy' was also
observed in deep grey matter structures, thalamus (Fig.
7C, D) and basal ganglia of infants with congenital NCL.
There, the aggregates varied greatly in size, with some
appearing to localize to proximal axons (Fig. 7C), and
some to the cell soma (Fig. 7D). Anti-hSA2-positive
deposits could also be seen within white matter tracts,
thus confirming their axonal localization. Within the cer-
ebellum, aSyn deposits were observed in the granular cell
Sheep expressing a homozygous mutant of Cathepsin D exhibit accumulation of phosphorylated α-synuclein in cingulate cortex Figure 6
Sheep expressing a homozygous mutant of Cathepsin D exhibit accumulation of phosphorylated α-synuclein in 
cingulate cortex. (A) Select cortical neurons (arrow) of cingulate gyrus in homozygous mutants (CathD mt/mt) show cyto-
plasmic immunostaining with Ser129-phosphorylated aSyn Ab. (B) Absence of Ser129-phosphorylated aSyn-reactivity in the 
cingulate gyrus of age-matched, heterozygous CTSD (CathD hetero) sheep brain. (C) Anti-ubiquitin antibody staining reveals 
extensive, often multiple, intra-cellular inclusion formation in neurons (arowhead) of affected sheep throughout the cortex 
including cingulate cortex. (D) Immunostaining for aSyn with polyclonal Ab, hSA-2, reveals abundant aSyn deposits and axonal 
swelling (arrows) in the internal capsule of homozygous mutant sheep but not wild-type (not shown) or heterozygous sheep 
(not shown). Scale bars, 100 μm in A, B, C, and 15 μm in D.Molecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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layer and deep white matter. Of note, these inclusions
were negative for Ser129-phosphorylation-specific aSyn
reactivity, and for ubiquitin (not shown). As expected, no
such aSyn abnormalities were seen in the control brain of
a neurologically normal infant processed in parallel (Fig.
7A).
Neurotoxicity of human α-synuclein in Drosophila is 
enhanced in ctsd-mutant flies
Over-expression of aSyn has been shown to be neurotoxic
in a variety of cellular and animal models. In order to
study the effect of endogenous CathD on aSyn-induced
neurotoxicity, we generated flies expressing human aSyn
in a ctsd-null background. In agreement with our previous
results [9], the retina was normal in one-day-old trans-
genic flies over-expressing wt human aSyn (Fig. 8A), but
showed mild, vacuole-carrying changes by day 30 (Fig.
8B). Flies expressing human aSyn in the absence of CathD
also had normal retinas at day one (Fig. 8C), but devel-
oped pronounced retinal degeneration within 30 days;
these progressive changes included the formation of
numerous vacuoles, thinning of the retina and loss of its
architecture (Fig. 8D). Importantly, fly CathD deficiency
by itself (without aSyn expression) did not cause this neu-
rodegeneration phenotype of the retina at day 30 (Fig. 8E;
[43]). These results indicated that neurotoxicity of aSyn is
enhanced in the absence of endogenous CathD expres-
sion.
Discussion
This report summarizes complementary investigations
into the role of a key lysosomal enzyme, CathD, in the
processing of aSyn. The in vivo results from three mamma-
lian and one insect species described here provide addi-
tional insights into the pathogenetic effects of CathD
Human neuronal ceroid lipofuscinosis due to Cathepsin D deficiency leads to intracellular accumulation of α-synuclein Figure 7
Human neuronal ceroid lipofuscinosis due to Cathepsin D deficiency leads to intracellular accumulation of α-
synuclein. (A) Paraffin-embedded brain sections of a neurologically normal infant (Control) stained with polyclonal aSyn Ab, 
hSA-2, show strong reactivity of the neuropil in the neocortex. (B) Immunohistochemistry of brain specimens from CathD-
deficient infants (CathD; n = 3), carried out in parallel, demonstrates marked reduction of neuropil staining. These sections 
also display scattered, cytoplasmic aSyn aggregates within neurons (identified by arrow). (C) Sections of the thalamus from the 
same individual as in B also reveal neuritic pathology (arrows), as well as (D) intracellular accumulation of aSyn, sometimes 
seen as a juxtanuclear inclusions (arrow). Scale bar, 15 μm.Molecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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deficiency, and identify in CathD a candidate for the
much sought after 'synucleinase' activity in vivo.
Our initial set of experiments focused on a dopaminergic
neuroblastoma cell culture model over-expressing aSyn
together with CathD (Fig. 1). CTSD expression reduced
aSyn concentrations in a manner that was dependent on
the level of newly synthesized CathD (Fig. 1A and 1B).
This effect could not be explained by a loss of cell viability,
as the integrity of our culture model was unchanged from
untransfected and vector-transfected cells in two standard
viability assays. Similarly, the effect of CTSD cDNA could
not be explained by a competition effect with the SNCA
plasmid for the protein synthesis machinery, because co-
expression of aSyn with Cathepsin L (CathL) or Cathepsin
E (CathE) under the same conditions did not cause a
reduction of aSyn concentrations (data not shown).
The simplest explanation for the effects of CTSD expres-
sion on aSyn is that CathD-mediated degradation of aSyn
within the lysosome was enhanced (see alternative expla-
nations below). For this explanation to be valid, aSyn
must have entered the lysosome by either macroau-
tophagy or CMA, or both, given that CathD is thought to
be active only at low pH. Several investigators have shown
that the Asp98 and Gln99 residues of aSyn facilitate recog-
nition by the Hsc70 chaperone and subsequent binding of
the aSyn/Hsc70 complex to the Lamp2a receptor during
CMA [26,28,52]. According to Cuervo et al., Ala30Pro and
Ala53Thr mutants of aSyn are able to bind to isolated lys-
osomal membranes but unable to translocate into the lys-
osomal lumen for degradation [28]. The fact that in our
cell culture system, the D98A/Q99A double mutant of
aSyn, as well as the Ala30Pro, Glu46Lys and Ala53Thr
mutants of aSyn were degradable by exogenous CathD
(Fig. 1C) suggests that, at the collection time point of 24
hours, the cells did not entirely rely on CMA as a means of
transporting aSyn into lysosomes, and that, rather, macro-
autophagy could be equally, or even more important than
CMA [26,52]. Likewise, changing the phosphorylation
state of human aSyn at Ser129 did not alter the proteolytic
synucleinase activity exhibited by CathD in our MES23.5
cell model. Of note, only select neurons in sheep cingulate
cortex deficient for lysosomal CathD activity (but not in
mouse or human brain) revealed evidence for abnormal
anti-Ser129-aSyn reactivity (Fig. 7 and data not shown).
Although the observed species difference could be caused
by a variety of factors, our cellular data argue that Ser129
phosphorylation of aSyn is not a universal pre-requisite
for CathD-induced aSyn degradation.
Western blotting analyses of our MES23.5 cell lysates
demonstrated that the CathD-induced reduction in aSyn
occurred without the concomitant appearance of either
low-molecular weight (LMW) or HMW species, as exam-
ined 24 hours after transfection. Of note, we had previ-
ously confirmed by Western blotting that our Abs are
capable of recognizing truncated aSyn species, (i.e., 10 to
12.5 kDa; see Additional file 2, Fig. S2) [46]. In particular,
the appearance of LMW species of aSyn would have indi-
cated incomplete proteolysis of aSyn, potentially at the C-
terminus. Such LMW aSyn-ΔC species are prone to aggre-
gate formation and have an enhancing effect on aSyn-
mediated toxicity [46,53-55]. Previous studies by Dufty et
al. [56] showed that calpain-mediated digestion of aSyn
could induce the formation of aSyn-ΔC species and for-
mation of HMW species. Recently, Sevlever et al. con-
firmed a proteolytic effect of both enzymes, calpain and
CathD, in in vitro biochemical studies and extended their
work to purified lysosomes from SNCA-expressing neu-
roblastoma cells [36].
In our SNCA  and  CTSD  over-expression model, we
observed a maximum effect of CathD-induced reduction
of excess aSyn levels that plateaued at ≤ 80 per cent of vec-
tor-transfected cells (Fig. 1B). We concluded from these
findings that a distinct pool of aSyn species (e.g., synaptic
vesicle-associated) is not amenable to CathD-mediated
Cathepsin D deficiency enhances α-synuclein toxicity in the retina of fly brain Figure 8
Cathepsin D deficiency enhances α-synuclein toxicity in the retina of fly brain. (A) Normal retina in one-day old, 
human SNCA cDNA-transgenic flies (α-Syn-WT; Feany and Bender, 2000). (B) At day 30 these flies show mild degeneration; 
arrow indicates vacuole. (C) Normal morphology of retina at day 1 in flies expressing human SNCA cDNA in the absence of 
endogenous fly cathD (α-Syn-WT, cathD-). (D) Marked degeneration of retinal neurons occurs by day 30 in flies ectopically 
expressing human SNCA cDNA in the absence of fly cathD. Note the appearance of numerous vacuoles, and the thinning and 
loss of retinal architecture. (E) Deletion of fly ctsd in the absence of aSyn expression (cathD-)does not cause retinal degenera-
tion at day 30. Scale bar, 20 μm.Molecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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aSyn degradation. To explore whether over-expression of
wt CTSD also reduces the concentration of endogenous
aSyn, we carried out additional Western blotting and
ELISA experiments in rodent MES23.5 and human SY5Y
neuroblastoma cells. In the background of normal lyso-
somal function and normal aSyn levels, we saw no con-
sistent, further reduction of endogenous aSyn levels by
ectopic CathD expression (not shown).
To examine the relevance of endogenous CathD expres-
sion on endogenous aSyn processing in vivo, we next
examined brain tissue from homozygous ctsd-/- mice [41].
We detected a consistent decrease in soluble aSyn proteins
in homozygous CathD deficient mouse brains versus those
of wt animals using Western blotting and ELISA (Figs. 2
and 3). This result was verified by quantitative 2D gel elec-
trophoresis, which showed a significant reduction of the
16 kDa aSyn spot in ctsd-/- mice (data not shown). Our
quantitative ELISA showed a comparable decrease in the
amount of soluble aSyn in NP-40 extracts (18.6 per cent)
and in SDS-extracts (20.0 per cent) of ctsd-/- mice com-
pared with controls (Fig. 3). This observation was in
agreement with our immunohistochemistry results from
the same mice that exhibited some reduction in aSyn
staining in the neuropil of ctsd-/- mice, particularly within
the thalamus (Fig. 5). Previously, we have confirmed that
CathD deficient mice show a decrease in pre-synaptic
markers in the ventral posterior nucleus of the thalamus,
and a > 30 per cent loss of neurons in its corresponding
target somatosensory cortex [34]. Because aSyn is a pre-
dominantly pre-synaptic protein, we surmised that the
reduction of soluble aSyn concentration recorded in our
ctsd-/- mice resulted – in part – from pre-synaptic abnor-
malities.
However, in parallel to the reduction of soluble aSyn
throughout the neuropil, we detected aSyn accumulation-
carrying neurons within many brain regions of 24-day old
ctsd-/- mice. This finding was substantiated by our obser-
vation of increased levels of insoluble species of oligo-
meric aSyn in the formic acid extracts of ctsd-/- mice (15%;
Fig. 4). (Of note, our current ELISA protocol is incompat-
ible with the quantification of aSyn in the presence of for-
mic acid). We concluded from these collective findings
that the presence of murine CathD is important for the
prevention of aSyn misprocessing and that its absence
facilitates the formation of aSyn aggregation in vivo. In
accordance, we speculate that the neuronal accumulation
of murine aSyn in ctsd-/- mice may represent early precur-
sor lesions to classical Lewy inclusions.
We next examined the role of mutant CathD protein
expression on sheep aSyn levels (Fig. 6). Homozygous
missense mutation in the ovine CTSD gene (Gln934Ala)
essentially abolishes the enzyme's proteolytic activity
(residual level, < 5 per cent), while heterozygotes retain 40
per cent activity and are phenotypically normal [50]. The
affected newborn lambs are weak, tremble and are unable
to stand. When sacrificed shortly after birth, their brains
are smaller and display mild cortical thinning, demyelina-
tion, neuronal loss, reactive astrocytosis and macrophage
infiltration, while visceral organs are spared. Classical
NCL-type changes and widespread ubiquitin-positive
inclusions within neurons were readily detected in the
homozygous animals (Fig. 6). In contrast to the more
extensive neuropil disruption and synucleinopathy seen
in ctsd-/- mouse brain, we detected more select neuronal
changes in homozygous CathD-mutant sheep, with
abnormal anti-aSyn staining in the cingulate cortex and in
the axons of deep white matter tracts. Intriguingly, synu-
cleinopathy of the cingulate cortex is a hallmark of human
dementia with Lewy bodies and advanced PD cases [6].
Unfortunately, no frozen material was available to deter-
mine whether insoluble, HMW oligomeric species of
ovine aSyn can be found biochemically in the cingulate
cortex.
Humans with congenital NCL are affected at birth and
survive only for days. Two mutations in the human CTSD
gene have been described to underlie a subset of congeni-
tal NCL cases [30,57]. Both mutations inactivate the
CathD enzyme, in that the insertion mutation,
c.764dupA, results in a premature stop-codon and rapid
degradation of the protein, while the c.299C > T mutation
leads to the production of an inactive but stable protein in
vivo. The brains of these infants show extreme cortical
atrophy, loss of neurons and myelin, as well as general-
ized gliosis [30,51,57]. In brain specimens of two affected
siblings from a NCL pedigree linked to CTSD and of one
unrelated patient with congenital NCL, anti-aSyn staining
of the neuropil was strongly reduced throughout the brain
(Fig. 7). Accumulation of aSyn was particularly pro-
nounced in the thalamus and basal ganglia, where the
neuronal soma appeared to be loaded with aSyn aggre-
gates, thereby morphologically resembling Lewy bodies of
the forebrain; however, in contrast to classical Lewy inclu-
sions these lesions were negative for ubiquitin and phos-
pho-Ser129-specific reactivity in the affected newborns
(not shown). Throughout the brains from these three
infants, smaller aSyn-positive grains appeared to localize
to neurites (Fig. 7B and 7C). Therefore, although the
degree of brain atrophy and neuronal loss was much more
severe in human infants with CathD deficiency than in
ctsd-/- mice, the aSyn-reactive histopathologies were very
similar between the two species, possibly because of the
complete loss of CathD protein expression in both.
Regarding the topographic distribution of aSyn accumula-
tion within the three species of CathD-deficient mam-
mals, it is interesting to note that the latter is markedlyMolecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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different from that of lipofuscin deposition in NCL dis-
eases. These autofluorescent accumulations are generally
widespread within cortical neurons in humans and sheep
affected by CathD deficiency and in the thalamus of ctsd-
/- mice, while the observed aSyn accumulations occurred
predominantly in the thalamus and basal ganglia in
humans, in the cingulate cortex of affected sheep, and in
the cerebral cortex of ctsd-/- mice.
Finally, our experiments using the established Drosophila
model of PD provided evidence for a modulatory effect of
endogenous CathD expression on aSyn toxicity in vivo
(Fig. 8). Deletion of the homologous CathD-encoding
gene promoted toxicity of ectopically expressed human
aSyn in the fly retina; these findings suggest that differ-
ences in the expression level of CathD (and by inference,
of other synucleinase-conferring proteases) may lower the
threshold for synucleinopathy in other brain regions and
species, too.
Importantly, our data do not demonstrate a direct interac-
tion between CathD as an enzyme and aSyn as its sub-
strate. Although such a relationship was suggested by in
vitro experiments in one study [35], purification of lyso-
somes from co-transfected MES23.5 cells and detailed
imaging analyses will be required to further test this
hypothesis. Intriguingly, aSyn transgenic mice show a
decrease in aSyn inclusions when immunized with recom-
binant aSyn, and this decrease was associated with a con-
comitant increase in CathD levels as well as co-
localization of CathD and aSyn [58]. Stefanis et al. [59]
also noted co-localization of a pool of aSyn with CathD in
their PC12 cell line-based experiments.
Indirect effects on aSyn accumulation by CathD defi-
ciency are also possible. For example, CTSD gene expres-
sion could activate another cathepsin or non-cathepsin
protease, and this second enzyme may process aSyn for
degradation. In this regard, it is interesting to note that
CathD possesses activity that is similar to pepsin, and that
pepsin can proteolytically activate Cathepsin F (CathF;
[60]); intriguingly, in our cell culture system, over-expres-
sion of CathF was able to reduce human aSyn levels, too,
with an efficiency similar to that of CathD, whereas over-
expression of CathE and CathL was ineffective (V.C.,
M.G.S., unpublished observations). It is noteworthy that
mice deficient in CathF develop a late-onset neurological
phenotype with gait disturbance, hind leg weakness and
tremors, which is associated with brain and spinal cord
pathology [61]; it will be interesting to discern whether
these mice also display biochemical and/or immunohis-
tochemical evidence of synucleinopathy.
Another possible mechanism for interaction between the
CTSD and SNCA genes in vivo is a change in lysosomal
constituency downstream of CathD protein expression.
Perturbations in the activities of several lysosomal sphin-
golipid-metabolising enzymes have been documented in
CathD-mutant sheep [31] and dogs [32], while ctsd-/-
mice accumulate phospho- and glyco-sphingolipids,
including gangliosides [62]. Since aSyn is a lipid- and gan-
glioside-binding protein [63-65], and since lipids can reg-
ulate the oligomerization of aSyn [45,66], it is plausible
that dysregulated lipid metabolism is a mechanism by
which CathD deficiency leads to aSyn misprocessing.
CathD is also known to exhibit activities that are unre-
lated to its enzymatic function [67-69]. It is therefore pos-
sible that non-proteolytic effects of CathD are essential in
aSyn processing, akin to its effects on the ras-MAPK path-
way [70]. Our data on aSyn processing in the cell soma
and neurites of mutant sheep brain, where CathD is over-
expressed but enzymatically disabled, would rather argue
against this theory. However, one cannot exclude with cer-
tainty that the homozygous mutation in CathD did not
also compromise its non-enzymatic functions, although
computational modeling did not predict the induction of
a conformational change in the sheep mutant (J.T., data
not shown).
Finally, our collective findings reported herein are in
remarkable agreement with many (but not all) of the find-
ings in the related report by Qiao and coworkers [71],
who independently discovered CathD as a critical enzyme
in the metabolism of neuronal aSyn using both in vitro
and in vivo experiments. Of note, Qiao et al. examined off-
spring of the same CathD-deficient mouse model that we
employed [41], and observed a reduction of truncated
aSyn species in ctsd-null mice, which we did not detect in
our protocol. In addition to possible technical and Ab-
related differences between the two reports, the slightly
younger age of our animals at the time of euthanasia
(post-natal day 24 versus 25) may also have contributed to
this discrepancy.
Conclusion
These findings add NCL disorders to the growing list of
human lysosomal storage diseases that feature mis-
processing of neuronal aSyn [72-74]. Our evidence for
altered processing and accumulation of insoluble species
of endogenous aSyn in three different mammals with
CathD deficiency indicates that its enzyme activity plays
an important role in aSyn metabolism. This concept is
supported by the pathogenesis replicated in our inverte-
brate  Drosophila  model, where the absence of CathD
markedly enhanced aSyn toxicity in vivo. Although we
have not yet revealed the molecular underpinnings for
this effect, we consider the finding of CathD as a facilitator
of 'synucleinase' activity an important, first lead in target
identification.Molecular Brain 2009, 2:5 http://www.molecularbrain.com/content/2/1/5
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The current treatment approaches for PD and related dis-
orders are symptomatic at best, are not yet driven by
molecular clues, and are invariably of limited duration. To
date, progress in cause-directed treatment of synuclein-
opathies has been prevented mostly by our limited knowl-
edge of the normal regulators that control aSyn steady-
state in vivo, from SNCA transcription to aSyn degrada-
tion. Further exploration of the mechanism by which
CathD promotes synucleinase activity holds the promise
for novel drug targets to ultimately treat PD (and related
disorders) at one if its root causes.
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